MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Thoratec profits leap 58 percent
Thoratec Corp. (NSDQ:THOR) posted net income of $12.6 million, or 21 cents per diluted share, on revenue of $97.6 million during the three months ended Jan. 1. That compares with net income of $8.0 million, or 14 cents per diluted share, on revenue of $81.0 million during the same period last year.
Read more
Accuray vaults out of the red
Accuray Inc. (NSDQ:ARAY) reported profits of $4.1 million, or 7 cents per diluted share, on revenue of $54.2 million during the three months ended Dec. 31. That compares with a loss of $1.2 million, or 2 cents per diluted share, on revenue of $57.3 million during the same period last year.
Read more
Cepheid leaps out of the red
Cepheid (NSDQ:CPHD) reported profits of $1.3 million, or 2 cents per diluted share, on sales of $58.7 million during the three months ended Dec. 31. That compares with a loss of $4.3 million, or 7 cents per diluted share, on sales of $49.2 million during the same period last year.
Read more
Abaxis profits, sales edge up
Abaxis Inc. (NSDQ:ABAX) reported net income of $3.8 million or 17 cents per diluted share, on sales of $35.9 million during the three months ended Dec. 31. That compares with net income of $3.4 million, or 15 cents per diluted share, on sales of $31 million during the same period last year.
Read more
ResMed’s net income increases 27 percent
ResMed Inc. (NYSE:RMD) recorded a profit of $58.5 million, or 37 cents per diluted share, on sales of $306 million during the three months ended Dec. 31. That compares with a profit of $46 million, or 30 cents per diluted share, on sales of $275.1 million during the same period last year.
Read more
Uroplasty sales edge up, but losses sink deeper
Uroplasty Inc. (NSDQ:UPI) reported a loss of $1.5 million, or 7 cents per diluted share, on revenue of $3.5 million during the three months ended Dec. 31. That compares with a loss of $386,736, or 3 cents per diluted share, on revenue of $3.1 million during the same period last year.
Read more
ZOLL Medical Corp. sales increase 8 percent
ZOLL Medical Corp. (NSDQ:ZOLL) posted net income of approximately $3.9 million, or 18 cents per diluted share, on sales of $113.2 million during the three months ended Jan. 2. That compares with net income of $2.3 million, or 11 cents per diluted share, on sales of $105.2 million during the same period last year.
Read more
Solos Endoscopy sales sink
Solos Endoscopy Inc. (OTC:SNDY) posted revenues of $90,005 during the three months ended Dec. 31. That compares with sales of $125,791 during the same period last year. The company plans to release a full earnings report for Q4 in the next 60 days.
Read more
Alcon profits get a 14 percent bump
Alcon Inc. (NYSE:ACL) reported profits of $521 million, or $1.71 per diluted share, on sales of $1.81 billion during the three months ended Dec. 31. That compares with profits of $458 million, or $1.51 per diluted share, on sales of $1.72 billion during the same period last year.
Read more
Cardica dives deeper into the red
Cardica Inc. (NSDQ:CRDC) recorded a loss of $3.3 million, or 13 cents per diluted share, on revenue of $1.2 million during the three months ended Dec. 31. That compares with a loss of $2.2 million, or 9 cents per diluted share, on sales of $1.1 million during the same period last year.
Read more
Omnicell Inc. profits halved
Omnicell Inc. (NSDQ:OMCL) reported a profit of $672,000, or 2 cents per diluted share, on revenue of $57.3 million during the three months ended Dec. 31. That compares with a profit of $1.3 million, or 4 cents per diluted share, on revenue of $56.3 million during the same period last year.
Read more